Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users

AIDS

Volumn 26, Issue 12, 2012, Pages 1491-1500

  Lima, Viviane Dias ^a,b   Nosyk, Bohdan ^a   Wood, Evan ^a,b   Kozai, Tsubasa ^a   Zhang, Wendy ^a   Chan, Keith ^a   Montaner, Julio S G ^a,b  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

antiretroviral therapy; boosted atazanavir; boosted protease inhibitor; efavirenz; effectiveness; injection drug use; NNRTI; population based cohort; viral load; virologic response

Indexed keywords

ATAZANAVIR; EFAVIRENZ; RITONAVIR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84864278662     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283550b68     Document Type: Article

References (34)

1. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al., International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
2. Hull MW, Lima VD, Hogg RS, Harrigan PR, Montaner JS. Epidemiology of treatment failure: a focus on recent trends. Curr Opin HIV AIDS 2009; 4:467-473.
3. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007; 21:685-692.
4. Lima VD, Hogg RS, Montaner JS. Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada. PLoS One 2010; 5:e10991.
5. Wood E, Kerr T, Tyndall MW, Montaner JS. A review of barriers and facilitators of HIV treatment among injection drug users. AIDS 2008; 22:1247-1256.
6. Krü si A, Wood E, Montaner J, Kerr T. Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy 2010; 21:4-9.
7. Ding L, Landon BE, Wilson IB, Wong MD, Shapiro MF, Cleary PD. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Intern Med 2005; 165:618-623.
8. Cescon AM, Cooper C, Chan K, Palmer AK, Klein MB, Machouf N, et al. Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multisite Canadian cohort. HIV Med 2011; 12:352-360.
9. McGowan CC, Weinstein DD, Samenow CP, Stinnette SE, Barkanic G, Rebeiro PF, et al. Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS One 2011; 6:e18462.
10. Walker AM. Confounding by indication. Epidemiology 1996; 7:335-336.
11. Garcia de la Hera M, Davo MC, Ballester-Añón R, Vioque J. The opinions of injecting drug user (IDUs) HIV patients and health professionals on access to antiretroviral treatment and health services in Valencia, Spain. Eval Health Prof 2011; 34:349-361.
12. Werb D, Mills EJ, Montaner JS, Wood E. Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis. Lancet Infect Dis 2010; 10:464-469.
13. Lert F, Kazatchkine MD. Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview. Int J Drug Policy 2007; 18:255-261.
14. Beyrer C, Malinowska-Sempruch K, Kamarulzaman A, Strathdee SA. 12 myths about HIV/AIDS and people who use drugs. Lancet 2010; 376:208-211.
15. Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction 2008; 103:1242-1257.
16. British Columbia Centre for Excellence in HIV/AIDS. The HAART Observational Medical Evaluation and Research (HOMER) study website. Available at: http://www.cfenet.ubc. ca/our-work/initiatives/homer. Accessed September 28, 2011.
17. LimaVD, BangsbergDR,Harrigan PR,Deeks SG, Yip B,Hogg RS, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr 2010; 55:460-465.
18. Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, Berger K, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006; 163:262-270.
19. Cook EF, Goldman L. Asymmetric stratification. An outline for an efficient method for controlling confounding in cohort studies. Am J Epidemiol 1988; 127:626-639.
20. Maldonado G, Greenland S. Simulation study of confounderselection strategies. Am J Epidemiol 1993; 138:923-936.
21. Lima VD, Geller J, Bangsberg DR, Patterson TL, Daniel M, Kerr T, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS 2007; 21:1175-1183.
22. Little RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health 2000; 21:121-145.
23. Mitra N, Heitjan DF. Sensitivity of the hazard ratio to nonignorable treatment assignment in an observational study. Stat Med 2000; 26:1398-1414.
24. Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 2003; 158:280-287.
25. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999; 150:327-333.
26. Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 2007; 45 (10 Suppl 2):S103-S107.
27. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-570.
28. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al., AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106.
29. Gazzard B, Duvivier C, Zagler C, Castagna A, Hill A, van Delft Y, et al. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. AIDS 2011; 25:2249-2258.
30. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al., AIDS Clinical Trials Group Study A5202 Team. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154:445-456.
31. Honda M, Ishisaka M, Ishizuka N, Kimura S, Oka S, Japanese Anti-HIV-1 QD Therapy Study Group. Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine. Intern Med 2011; 50:699-705.
32. +<200 cell/mm3 in Mexico. J Acquir Immune Defic Syndr 2010; 53:582-588.
33. Domingo P, Suárez-Lozano I, Torres F, Teira R, Lopez-Aldeguer J, Vidal F, et al. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a nonrandomized comparison from the VACH cohort. J Antimicrob Chemother 2008; 61:1348-1358.
34. Hirnschall G, Schwartländer B. Treatment 2.0: catalysing the next phase of scale-up. Lancet 2011; 378:209-211.